IP Library Patent Application 14684129
Patent Application
App. No. 14/684,129

SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/684,129
Abstract

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Claims (16)

1 . A method of differentiating progenitor cells into pancreatic β cells in vitro, the method comprising culturing a cluster of the progenitor cells in suspension in a culture medium comprising the following compounds: a thyroid hormone signaling pathway activator and a transforming growth factor β (TGF-β) signaling pathway inhibitor, thereby differentiating the progenitor cells into pancreatic β cells, wherein the pancreatic β cells exhibit an in vitro glucose-stimulated insulin secretion response to at least a first glucose challenge and a second glucose challenge when the first glucose challenge and the second glucose challenge are applied sequentially.

2 . The method of claim 1 , wherein the progenitor cells comprise an insulin-positive endocrine cell.

3 . The method of claim 1 , wherein the progenitor cells comprise a PDX1-positive progenitor cell.

4 . The method of claim 1 , wherein the thyroid hormone signaling pathway activator is triiodothyronine.

5 . The method of claim 4 , wherein the concentration of the triiodothyronine is at least 0.1 μM.

6 . The method of claim 1 , wherein the TGF-β signaling pathway inhibitor is Alk5 inhibitor II.

7 . The method of claim 6 , wherein the concentration of the Alk5 inhibitor II is at least 100 nM.

8 . The method of claim 1 , wherein the culturing comprises changing the culture medium at least every other day.

9 . The method of claim 1 , wherein the culturing lasts for at least seven days.

10 . The method of claim 1 , wherein the culture medium is a serum-free culture medium.

11 . The method of claim 1 , wherein the progenitor cells are cultured in the presence of a low-adherent substrate.

12 . The method of claim 1 , wherein the progenitor cells are human progenitor cells.

13 . The method of claim 1 , wherein the progenitor cells are generated from stem cells.

14 . The method of claim 13 , wherein the stem cells are embryonic stem cells.

15 . The method of claim 13 , wherein the stem cells are induced pluripotent stem cells.

16 . The method of claim 1 , wherein the non-native pancreatic β cells exhibit an in vitro glucose-stimulated insulin secretion response to a first glucose challenge, a second glucose challenge, and a third glucose challenge, when the first glucose challenge, the second glucose challenge and the third glucose challenge are applied sequentially.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2016
From: MELTON, DOUGLAS A
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 037957/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2016
From: PETERSON, QUINN P.; PAGLIUCA, FELICIA J.; MELTON, DOUGLAS A; MILLMAN, JEFFREY R.; SEGEL, MICHAEL SARIS; GÜRTLER, MADS; HOWARD HUGHES MEDICAL INSTITUTE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 038066/0712 →
APPOINTMENT OF AGENT Recorded Mar 11, 2016
From: HOWARD HUGHES MEDICAL INSTITUTE
To: MELTON, DOUGLAS A.
Reel/Frame 038066/0807 →